COMMUNIQUÉS West-GlobeNewswire

Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

08/05/2024 - 14:00

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics , a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today [...]

USARAD, Nanox’s Teleradiology Subsidiary, Awarded Accreditation from The Joint Commission

08/05/2024 - 14:00

Company earns Gold Seal of Approval® for Ambulatory Health Care Accreditation PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical [...]

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

08/05/2024 - 14:00

CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta [...]

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

08/05/2024 - 14:00

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, [...]

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

08/05/2024 - 14:00

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by [...]

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

08/05/2024 - 14:00

Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 NEW YORK, May 08, 2024 (GLOBE NEWSWIRE [...]

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

08/05/2024 - 14:00

Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8 ® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p [...]

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

08/05/2024 - 14:00

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]

Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives

08/05/2024 - 14:00

SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual [...]

Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research

08/05/2024 - 14:00

Expanded Activities Position Rakovina Therapeutics to Capitalize on AI Partnerships with The University of British Columbia and Pharma Inventor Inc. VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina [...]

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

08/05/2024 - 14:00

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare [...]

BioAtla to Participate in the Citizens JMP Life Sciences Conference

08/05/2024 - 14:00

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

08/05/2024 - 14:00

LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

08/05/2024 - 14:00

― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial― ― [...]

ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024

08/05/2024 - 14:00

AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager, will be presenting: [...]

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

08/05/2024 - 14:00

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) [...]

TytoCare and Urgent Care Association to Host Major Health System Leaders for Rural & Urgent Care Clinic Virtual Summit

08/05/2024 - 14:00

Leaders from Corewell Health, Avel eCare, Sanford Health, Urgent Care Association, and others will share how their remote care initiatives are improving healthcare access NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- [...]

ArriVent BioPharma Reports First Quarter 2024 Financial Results

08/05/2024 - 14:00

Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research (“AACR”) Annual Meeting Dosed first patient in Phase 1b combination study of firmonertinib and ICP- [...]

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

08/05/2024 - 14:00

BASKING RIDGE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]